Search Results - "Teichman, Sam"

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial by Teerlink, John R, Prof, Cotter, Gad, MD, Davison, Beth A, PhD, Felker, G Michael, MD, Filippatos, Gerasimos, Prof, Greenberg, Barry H, Prof, Ponikowski, Piotr, Prof, Unemori, Elaine, PhD, Voors, Adriaan A, Prof, Adams, Kirkwood F, MD, Dorobantu, Maria I, Prof, Grinfeld, Liliana R, MD, Jondeau, Guillaume, Prof, Marmor, Alon, Prof, Masip, Josep, Prof, Pang, Peter S, MD, Werdan, Karl, Prof, Teichman, Sam L, MD, Trapani, Angelo, PhD, Bush, Christopher A, PhD, Saini, Rajnish, MD, Schumacher, Christoph, PhD, Severin, Thomas M, MD, Metra, Marco, Prof

“…Summary Background Serelaxin, recombinant human relaxin-2, is a vasoactive peptide hormone with many biological and haemodynamic effects. In a pilot study,…”
Get full text

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program: Correlation With Outcomes by METRA, Marco, COTTER, Gad, DOROBANTU, Maria I, GRINFELD, Liliana, JONDEAU, Guillaume, MARMOR, Alon, MASIP, Josep, PANG, Peter S, WERDAN, Karl, PRESCOTT, Margaret F, EDWARDS, Christopher, TEICHMAN, Sam L, DAVISON, Beth A, TRAPANI, Angelo, BUSH, Christopher A, SAINI, Rajnish, SCHUMACHER, Christoph, SEVERIN, Thomas, TEERLINK, John R, MICHAEL FELKER, G, FILIPPATOS, Gerasimos, GREENBERG, Barry H, PONIKOWSKI, Piotr, UNEMORI, Elaine, VOORS, Adriaan A, ADAMS, Kirkwood F

“…The aim of this study was to assess the effects of serelaxin on short-term changes in markers of organ damage and congestion and relate them to 180-day…”
Get full text

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study by Teerlink, John R, Prof, Metra, Marco, Prof, Felker, G Michael, MD, Ponikowski, Piotr, Prof, Voors, Adriaan A, MD, Weatherley, Beth Davison, PhD, Marmor, Alon, Prof, Katz, Amos, Prof, Grzybowski, Jacek, MD, Unemori, Elaine, PhD, Teichman, Sam L, MD, Cotter, Gad, MD

“…Summary Background Most patients admitted for acute heart failure have normal or increase blood pressure. Relaxin is a natural human peptide that affects…”
Get full text

Safety and Efficacy of Vocacapsaicin for Management of Postsurgical Pain: A Randomized Clinical Trial by Shafer, Steven L, Teichman, Sam L, Gottlieb, Ira J, Singla, Neil, Minkowitz, Harold S, Leiman, David, Vaughn, Benjamin, Donovan, John F

“…Nonopioid management of postsurgical pain remains a major unmet need. Few studies have evaluated transient receptor potential vanilloid subfamily member 1…”
Get full text

Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies) by Davison, Beth A., Takagi, Koji, Edwards, Christopher, Adams, Kirkwood F., Butler, Javed, Collins, Sean P., Dorobantu, Maria I., Ezekowitz, Justin A., Filippatos, Gerasimos, Greenberg, Barry H., Levy, Phillip D., Masip, Josep, Metra, Marco, Pang, Peter S., Ponikowski, Piotr, Severin, Thomas M., Teerlink, John R., Teichman, Sam L., Voors, Adriaan A., Werdan, Karl, Cotter, Gad

“…Previous studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) is a novel yet readily evaluable inflammatory biomarker that may be useful for…”
Get full text

Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial by Voors, Adriaan A., Tamby, Jean‐François, Cleland, John G., Koren, Michael, Forgosh, Leslie B., Gupta, Dinesh, Lund, Lars H., Camacho, Albert, Karra, Ravi, Swart, Henk P., Pellicori, Pierpaolo, Wagner, Frank, Hershberger, Ray E., Prasad, Narayana, Anderson, Robert, Anto, Anu, Bell, Kaylyn, Edelberg, Jay M., Fang, Liang, Henze, Marcus, Kelly, Cynthia, Kurio, Gregory, Li, Wanying, Wells, Kate, Yang, Chun, Teichman, Sam L., Rio, Carlos L., Solomon, Scott D.

“…Aims Both left ventricular (LV) and left atrial (LA) dysfunction and remodelling contribute to adverse outcomes in heart failure with reduced ejection fraction…”
Get full text

Effects of serelaxin in patients admitted for acute heart failure: a meta‐analysis by Teerlink, John R., Davison, Beth A., Cotter, Gad, Maggioni, Aldo P., Sato, Naoki, Chioncel, Ovidiu, Ertl, Georg, Felker, G. Michael, Filippatos, Gerasimos, Greenberg, Barry H., Pang, Peter S., Ponikowski, Piotr, Edwards, Christopher, Senger, Stefanie, Teichman, Sam L., Nielsen, Olav Wendelboe, Voors, Adriaan A., Metra, Marco

“…Aims The effectiveness and safety of 48 h intravenous 30 μg/kg/day serelaxin infusion in acute heart failure (AHF) has been studied in six randomized,…”
Get full text

Intravenous Recombinant Human Relaxin in Compensated Heart Failure: A Safety, Tolerability, and Pharmacodynamic Trial by Dschietzig, Thomas, MD, Teichman, Sam, MD, Unemori, Elaine, MD, Wood, Susy, Boehmer, Julia, Richter, Christoph, MD, Baumann, Gert, MD, Stangl, Karl, MD

“…Abstract Background Relaxin is upregulated in human heart failure (HF). Animal and clinical data suggest beneficial hemodynamic and renal effects from…”
Get full text

Scientific Rationale and Design of a Phase I Safety Study of Relaxin in Women with Severe Preeclampsia by Unemori, Elaine, Sibai, Baha, Teichman, Sam L

“…The pathophysiology of preeclampsia involves profound systemic vasoconstriction. Its etiology may be related to reduced blood flow to the placenta, leading to…”
Get full text

Design of the RELAXin in Acute Heart Failure Study by Ponikowski, Piotr, MD, Metra, Marco, MD, Teerlink, John R., MD, Unemori, Elaine, PhD, Felker, G. Michael, MD, Voors, Adriaan A., MD, PhD, Filippatos, Gerasimos, MD, Greenberg, Barry, MD, Teichman, Sam L., MD, Severin, Thomas, MD, Mueller-Velten, Guenther, MSc, Cotter, Gad, MD, Davison, Beth A., PhD

“…Background Acute heart failure (AHF) remains a major public health burden with a high prevalence and poor prognosis. Relaxin is a naturally occurring peptide…”
Get full text

Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF by Voors, Adriaan A., Davison, Beth A., Felker, G. Michael, Ponikowski, Piotr, Unemori, Elaine, Cotter, Gadi, Teerlink, John R., Greenberg, Barry H., Filippatos, Gerasimos, Teichman, Sam L., Metra, Marco

“…Aims We aimed to determine the relation between baseline systolic blood pressure (SBP), change in SBP, and worsening renal function (WRF) in acute heart…”
Get full text

Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction by Teichman, Sam L, Thomson, Kassandra S, Regnier, Michael

“…Chronic inotropic therapy is effective for the treatment of heart failure with reduced ejection fraction, but has been limited by adverse long-term safety…”
Get more information

Relaxin: Review of Biology and Potential Role in Treating Heart Failure by Teichman, Sam L., Unemori, Elaine, Teerlink, John R., Cotter, Gad, Metra, Marco

“…Relaxin is a naturally occurring human peptide initially identified as a reproductive hormone. More recently, relaxin has been shown to play a key role in the…”
Get full text

Relaxin, a pleiotropic vasodilator for the treatment of heart failure by Teichman, Sam L., Unemori, Elaine, Dschietzig, Thomas, Conrad, Kirk, Voors, Adriaan A., Teerlink, John R., Felker, G. Michael, Metra, Marco, Cotter, Gad

“…Relaxin is a naturally occurring peptide hormone that plays a central role in the hemodynamic and renovascular adaptive changes that occur during pregnancy…”
Get full text

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study by Metra, Marco, Teerlink, John R., Felker, G. Michael, Greenberg, Barry H., Filippatos, Gerasimos, Ponikowski, Piotr, Teichman, Sam L., Unemori, Elaine, Voors, Adriaan A., Weatherley, Beth Davison, Cotter, Gad

“…Aims Although dyspnoea is the most common cause of admission for acute heart failure (AHF), more needs to be known about its clinical course and prognostic…”
Get full text

SGS742: the first GABAB receptor antagonist in clinical trials by FROESTL, Wolfgang, GALLAGHER, Michela, JENKINS, Helen, MADRID, Annette, MELCHER, Thorsten, TEICHMAN, Sam, MONDADORI, Cesare G, PEARLMAN, Rodney

Get full text

Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs by Teichman, Sam L, Maisel, Alan S, Storrow, Alan B

“…Acute heart failure is a common condition associated with considerable morbidity, mortality, and cost. However, evidence-based data on treating heart failure…”
Get more information

Translation of Cardiac Myosin Activation With 2-Deoxy-ATP to Treat Heart Failure Via an Experimental Ribonucleotide Reductase-Based Gene Therapy by Thomson, Kassandra S., PhD, Odom, Guy L., PhD, Murry, Charles E., MD, PhD, Mahairas, Gregory G., PhD, Moussavi-Harami, Farid, MD, Teichman, Sam L., MD, Chen, Xiaolan, PhD, Hauschka, Stephen D., PhD, Chamberlain, Jeffrey S., PhD, Regnier, Michael, PhD

“…Summary Despite recent advances, chronic heart failure remains a significant and growing unmet medical need, reaching epidemic proportions carrying substantial…”
Get full text

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program by Metra, Marco, MD, Cotter, Gad, MD, Davison, Beth A., PhD, Felker, G. Michael, MD, MHS, Filippatos, Gerasimos, MD, Greenberg, Barry H., MD, Ponikowski, Piotr, MD, PhD, Unemori, Elaine, PhD, Voors, Adriaan A., MD, PhD, Adams, Kirkwood F., MD, Dorobantu, Maria I., MD, Grinfeld, Liliana, MD, Jondeau, Guillaume, MD, PhD, Marmor, Alon, MD, Masip, Josep, MD, Pang, Peter S., MD, Werdan, Karl, MD, Prescott, Margaret F., PhD, Edwards, Christopher, BS, Teichman, Sam L., MD, Trapani, Angelo, PhD, Bush, Christopher A., PhD, Saini, Rajnish, MD, Schumacher, Christoph, PhD, Severin, Thomas, MD, Teerlink, John R., MD

“…Objectives The aim of this study was to assess the effects of serelaxin on short-term changes in markers of organ damage and congestion and relate them to…”
Get full text

A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology by Arya, Anita, Silberbauer, John, Teichman, Sam L., Milner, Peter, Sulke, Neil, Camm, A. John

“…Aims ATI-2042 (budiodarone) is a chemical analogue of amiodarone with a half life of 7 h. It is electrophysiologically similar to amiodarone, but may not have…”
Get full text